Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer

[1]  T. Mizowaki,et al.  Investigation of 4D dose in volumetric modulated arc therapy-based stereotactic body radiation therapy: does fractional dose or number of arcs matter? , 2020, Journal of radiation research.

[2]  G. Pond,et al.  A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. , 2019, International journal of radiation oncology, biology, physics.

[3]  I. Vollmer,et al.  Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer , 2019, Clinical and Translational Oncology.

[4]  T. Yamanaka,et al.  A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L , 2018, British Journal of Cancer.

[5]  J. Bradley,et al.  Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  S. Senan,et al.  Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial. , 2018, International journal of radiation oncology, biology, physics.

[7]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[8]  J. Galvin,et al.  Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Jöckel,et al.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[11]  T. Yamanaka,et al.  S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Multi-Institutional Phase II Trial (West Japan Thoracic Oncology Group 3706) , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Suresh Senan,et al.  Dosimetric impact of interplay effect on RapidArc lung stereotactic treatment delivery. , 2011, International journal of radiation oncology, biology, physics.

[13]  Masaaki Kawahara,et al.  Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Schmidt.  Meta-Analysis , 2008 .

[15]  S. Anthony,et al.  Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer , 1996, Annals of Internal Medicine.

[16]  J. Pignon,et al.  Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: A meta‐analysis , 1996, Cancer.

[17]  P. Rubin,et al.  Long‐term observations of the patterns of failure in patients with unresectable non‐oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group , 1987, Cancer.

[18]  W. Grove.  Statistical Methods for Rates and Proportions, 2nd ed , 1981 .

[19]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .